a. Analytical study | |||
DST Result | Xpert MTB/RIF assay result | Number | Sequence resulta |
RIF-resistant | MTB not detected | 3 | MTB |
RIF-susceptible | MTB not detected | 1 | MTB |
RIF-resistant | RIF Resistance not detected | 2 | 2 of 2 wild type rpoB core |
RIF-susceptible | RIF Resistance detected | 9 | 8 of 9 with resistance associated mutations in rpoB core: three with 531 ttg, three with 526 tgc, one with 516 gtc, one with 526 ctc 1 of 9 wild type rpoB core |
b. Combined clinical studies | |||
Culture/DST result | Xpert MTB/RIF assay result | Number | Bi-directional sequencing |
Smear-positive specimens | |||
MTB positive | MTB not detected | 1 | MTB |
MTB negativeb | MTB detected | 1 | N/A |
Smear-negative specimens | |||
MTB positive | MTB not detected | 28 | MTB |
MTB negativec | MTB detected | 7 | N/A |
Rifampin resistance results | |||
MTB positive/RIF- resistant | MTB detected; RIF Resistance NOT detected | 1 | Resistance associated mutation in rpoB core: 531 ttg with evidence of wild type mixture |
MTB positive/RIF- susceptible | MTB detected; RIF Resistance detected | 4 | 2 of 4 with resistance associated mutations in rpoB core: both with 533 ccg |
2 of 4 with susceptible associated rpoB core: one wild-type and one 514 ttt (silent) mutation. |